Results 111 to 120 of about 20,735 (212)

A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. [PDF]

, 2021
BACKGROUND: The spread of SARS-CoV-2 has caused a worldwide pandemic that has affected almost every aspect of human life. The development of an effective COVID-19 vaccine could limit the morbidity and mortality caused by infection and may enable the ...
Bailey, Dalan, Barrett, Jordan, Belij-Rammerstorfer, Sandra, Burton, Oliver T, Conceicao, Carina, Evans-Bailey, Nicola, Foster, William S, Fra-Bidó, Sigrid, Gilbert, Sarah C, Innocentin, Silvia, Lambe, Teresa, Le Lee, Jia, Linterman, Michelle A, Liston, Adrian, Noble, Carly, Silva-Cayetano, Alyssa, Spencer, Alexandra J, Thakur, Nazia, Wright, Daniel   +18 more
core   +1 more source

Cytomegalovirus‐Based Viral Vectors Elicit Robust Systemic and Tissue‐Resident Immune Response Against SARS‐CoV‐2 Antigens

European Journal of Immunology, Volume 56, Issue 2, February 2026.
We developed murine CMV‐based viral vectors expressing SARS‐CoV‐2 spike antigen and compared immune response following intraperitoneal and intranasal delivery. Route of vaccine administration shaped antibody and CD8+ T cell response magnitude, kinetics, and tissue residency, highlighting the potential of CMV vectors for induction of protective lung ...
Maja Cokarić Brdovčak, Jelena Materljan Franki, Marko Šustić, Karmela Miklić, Magdalena Medved, Lydia Gaćina, Tina Ružić, Stipan Jonjić, Ilija Brizić, Astrid Krmpotić   +9 more
wiley   +1 more source

A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease

Pathogens, 2019
The mosquito-borne chikungunya virus (CHIKV) has become a major global health problem. Upon infection, chikungunya fever (CHIKF) can result in long-term joint pain and arthritis, and despite intense research, no licensed vaccine for CHIKV is available ...
Rafael Kroon Campos, Lorena Preciado-Llanes, Sasha R. Azar, Cesar Lopez-Camacho, Arturo Reyes-Sandoval, Shannan L. Rossi   +5 more
doaj   +1 more source

Humoral epitope dominance and immune imprinting by SARS‐CoV‐1 and SARS‐CoV‐2 vaccines

Immunology &Cell Biology, Volume 104, Issue 2, Page 150-167, February 2026.
We investigated Modified Vaccinia Ankara (MVA) vaccine candidates expressing the SARS‐CoV‐1 or SARS‐CoV‐2 Spike, as a primary or booster immunization, for their ability to induce antibodies targeting different epitopes on the SARS‐CoV‐2 RBD and broad cross‐reactive or cross‐neutralizing responses in C57BL/6 and antibody humanized (Ig‐humanized) mice ...
Deborah L Burnett, Ania Moxon, Anupriya Aggarwal, Katherine JL Jackson, Catherine Cotter, Anouschka Akerman, Amanda Russell, Rachel Kalman, David Langley, Jake Y Henry, Daniel Christ, Rowena A Bull, Robert Brink, Anthony D Kelleher, Hans‐Martin Jäck, Stuart Turville, Bernard Moss, Christopher C Goodnow   +17 more
wiley   +1 more source

To what extent AstraZeneca ChAdOx1 nCoV-19 vaccine is safe and effective? Rapid systematic review

The Egyptian Journal of Bronchology, 2022
Until now, there are more than two hundred million confirmed cases of COVID-19 including more than seven million deaths. Clinical trials of all three vaccines authorized for use in the UK (Pfizer–BioNTech, Oxford–AstraZeneca, and Moderna) have reported ...
Aliae A. R. Mohamed Hussein, Islam H. Ibrahim, Islam A. Mahmoud, Marwa Amary, Reem Sayad   +4 more
doaj   +1 more source

Humoral immune responses to ChAdOx1 nCoV-19 in children [PDF]

COVID-19 vaccination of children and young people is recommended in some countries. Data on immune responses induced by COVID-19 vaccines in children have been reported less widely than for adults.
Li, Grace
core   +2 more sources

IL‐10‐ and IL‐13‐Biased T Cell Responses to SARS‐CoV‐2 Vaccination in Diabetes

European Journal of Immunology, Volume 55, Issue 12, December 2025.
How the immune system of people with diabetes responds to vaccination against respiratory viruses is not well understood. Using activation‐induced markers to identify, quantify, and functionally characterize Spike‐specific CD4+ and CD8+ T cells after SARS‐CoV‐2 vaccination, we show defects in T cell memory maintenance and an IL‐10 and IL‐13‐dominated T
Emma M. Jones, Caren Sourij, Martin Stradner, Peter Schlenke, Nazanin Sereban, Othmar Moser, Rachael Quinlan, Charlotte‐Eve Short, Benjamin H. L. Harris, Michael Fertleman, Graham P. Taylor, Nick Oliver, Harald Sourij, Margarita Dominguez‐Villar   +13 more
wiley   +1 more source

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial [PDF]

, 2022
BACKGROUND: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain.
Aley, Parvinder K, Andrews, Nick, Babbage, Gavin, Bawa, Tanveer, Baxter, David, Bula, Marcin, Cathie, Katrina, Charlton, Sue, Chatterjee, Krishna, Cornelius, Victoria, COV-BOOST study group, ., Dodd, Kate, Enever, Yvanne, Faust, Saul N, Feng, Shuo, Goodman, Anna L, Green, Christopher A, Hallis, Bassam, Harndahl, Linda, Haughney, John, Hicks, Alexander, Holliday, Kyra, Janani, Leila, Kanji, Nasir, Lambe, Teresa, Libri, Vincenzo, Liu, Xinxue, Llewelyn, Martin J, Maallah, Mina, McGregor, Alastair C, Minassian, Angela M, Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Munro, Alasdair PS, Nguyen-Van-Tam, Jonathan S, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Qureshi, Ehsaan, Rampling, Tommy, Ramsay, Mary, Read, Robert C, Regan, Karen, Saich, Stephen, Saralaya, Dinesh, Sharma, Sunil, Sheridan, Ray, Snape, Matthew D, Thomson, Emma C, Todd, Shirley, Twelves, Chris, van der Klaauw, Agatha A   +55 more
core  

Parsonage–Turner Syndrome and Vocal Fold Paresis Following Soberana 2 FINLAY‐FR‐2 COVID‐19 Vaccination: A Case Report

Clinical Case Reports, Volume 13, Issue 11, November 2025.
ABSTRACT This case report presents a 58‐year‐old male who developed Parsonage–Turner syndrome (PTS) and vocal cord paresis after receiving the Soberana 2 FINLAY‐FR‐2 COVID‐19 vaccine. The patient experienced escalating pain and weakness in both shoulders and upper limbs after each vaccine dose, with subsequent neurological symptoms including headaches,
Amir‐Hassan Bordbari, Negar Heidari, Narges Karimi   +2 more
wiley   +1 more source

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults

Scientific Reports, 2023
In this single-center observational study with 1,206 participants, we prospectively evaluated SARS-CoV-2-antibodies (anti-S RBD) and vaccine-related adverse drug reactions (ADR) after basic and booster immunization with BNT162b2- and ChAdOx1-S-vaccines ...
Simon Dedroogh, Sven Schmiedl, Petra A. Thürmann, Katharina Graf, Sebastian Appelbaum, Reinhard Koß, Christian Theis, Zewarudin Zia, Jürgen Tebbenjohanns, Serge C. Thal, Michael Dedroogh   +10 more
doaj   +1 more source